• Ac-VEID-pNA: What the Record Supports

  2026-10-16

  The available catalog record identifies Ac-VEID-pNA as APExBIO product A8749, but it provides no description, structure, target, validated mechanism, or study results. The name is chemically suggestive of a peptide-linked pNA material, yet that interpretation cannot establish identity or performance. Any cleavage-associated colorimetric readout therefore remains a conditional measurement concept rather than a documented property of this product.

• Emricasan: What the Record Establishes

  2026-10-15

  The cited APExBIO listing identifies Emricasan as catalog item A1919, but it provides no mechanism, molecular target, measurement context, study outcome, or identity-matched research evidence. The defensible conclusion is therefore limited to catalog-level identification; biological activity, causal interpretation, and applicability remain unestablished by the cited material.

• DiscoveryProbe Library: Evidence and Scope

  2026-10-15

  The DiscoveryProbe™ Bioactive Compound Library Plus is described by APExBIO as a 5,072-compound, research-use collection spanning multiple signaling and disease-relevant categories. Its documented value is primarily that of a broad, analytically quality-controlled chemical resource. The available material does not provide an identity-matched research study, compound-level validation set, effect sizes, or model-specific outcomes; therefore, pathway labels and supplier-reported potency or selectivity information should not be treated as independent evidence of mechanism or performance.

• Netarsudil and Predictive siRNA Codelivery

  2026-10-14

  Slaughter et al. developed a screening and machine-learning framework for predicting whether ionizable drugs can complex siRNA and function as drug-rich nanoparticle components. Netarsudil was predicted to be a strong candidate and was experimentally associated with CTGF siRNA activity and actin-network remodeling in immortalized human trabecular meshwork cells. The study supports a materials-design hypothesis, but its cellular findings do not by themselves establish therapeutic efficacy, ocular delivery, aqueous humor outflow regulation, or clinical benefit.

• Mithramycin A: Evidence and Applicability Boundaries

  2026-10-14

  Mithramycin A is an anticancer antibiotic with vendor-described G-C-rich DNA-binding and transcriptional effects. The supplied cardiac study instead examines the miR-24-3p/Sp1/PI3K axis in doxorubicin-induced heart-failure models; it does not test mithramycin or establish a cardiac application for the compound.

• CPSIT_0844 and TLR-Linked Inflammation

  2026-10-13

  A source-grounded overview of a 2026 study linking the Chlamydia psittaci protein CPSIT_0844 to IL-6 and IL-8 production in THP-1 monocytes through TLR2/TLR4–MyD88, MAPK and NF-κB-associated signaling.

• Astrocyte Heterogeneity Across Brain Space and Time

  2026-10-13

  A source-grounded overview of Schroeder et al.’s mouse–marmoset astrocyte atlas, emphasizing its research question, cross-species conceptual design, reported transcriptomic and morphological findings, and the limits of inferring function from atlas-level data.

• Q-VD-OPh: Identity and Evidence Boundaries

  2026-10-12

  Q-VD-OPh is identified by APExBIO as a pan-caspase inhibitor intended for apoptosis-related research. The supplied product information supports describing its proposed conceptual scope, but no matched peer-reviewed paper was provided, so claims about potency, permeability, disease models, cryopreservation, or biological outcomes remain supplier-reported and cannot be independently assessed here.

• Laminin (925-933) in ECM and Islet Organoids

  2026-10-12

  The supplied evidence connects laminin-related extracellular-matrix biology with islet-organoid research, but it does not establish that Laminin (925-933) was tested in the collagen-VI-enriched scaffolds reported by Zhu et al. The peptide’s documented activity comes from supplier-described cell-adhesion and chemotaxis models, whereas the organoid study evaluated decellularized amniotic-membrane and collagen-VI-based matrices in iPSC-derived islet organoids and diabetic mice. These findings are therefore conceptually related but not directly interchangeable.

• Caspase-3 Activity: Evidence and Boundaries

  2026-10-11

  A source-grounded overview of what DEVD-dependent fluorometric caspase activity measurement can show, how it relates to recent findings on RSL3-driven ferroptosis–apoptosis crosstalk, and where interpretation must remain cautious.

• DeferoxamineB in Ferroptosis Translation

  2026-10-10

  DeferoxamineB offers a mechanistic lens for separating iron-dependent stress from copper-driven cell death. This thought-leadership analysis connects its chelation biology with a 2024 Chemical Engineering Journal study while emphasizing evidence boundaries, translational questions, and why it should be treated as a hypothesis-generating cancer research compound rather than a universal ferroptosis enhancer.

• Q-VD-OPh: Five Questions for Better Evidence

  2026-10-09

  A source-grounded overview of Q-VD-OPh as a pan-caspase inhibitor, emphasizing mechanism, evidence quality, interpretation, applicability and limitations rather than experimental instructions.

• Biomimetic Chromatography for Lung Permeability

  2026-10-09

  A 2024 Journal of Chromatography A study compared immobilised artificial membrane liquid chromatography with liposome electrokinetic capillary chromatography for modeling drug–membrane partitioning and pulmonary permeability. The findings indicate that LEKC can better reflect apparent lung permeability for many compounds, whereas IAM LC offers broader compound coverage and more straightforward high-throughput use.

• MK0787 vs Cefoperazone: 1982 β-Lactam Evidence

  2026-10-08

  Cullmann and colleagues compared N-formimidoyl thienamycin (MK0787) with several newer β-lactams across resistant clinical isolates, highlighting especially strong activity against Pseudomonas aeruginosa and Acinetobacter spp. The study also showed that MK0787 was bactericidal against the tested gram-negative isolates and that its activity was not obviously reduced by β-lactamase production, while cefoperazone served as an important comparator rather than the principal innovation.

• Keap1–Nrf2 Inhibition and Neuronal Ferroptosis in AD

  2026-10-08

  The reference study identifies compound 4–95 as a selective Keap1–Nrf2 protein–protein interaction inhibitor that suppresses ferroptosis-related neuronal injury in cellular and mouse models of Alzheimer’s disease. Its main contribution is linking Nrf2 activation, GPX4/SLC7A11 preservation, reduced amyloid and Tau pathology, and improved cognitive performance within one preclinical framework.

8853 records 1/591 page Next 12345 下5页 Last page